This storyline ended. Last forecast Tuesday, 17 November 2026.Read today’s paper →

Forecast · not a report of real eventsBuilt Tuesday, 17 November 2026 from that day’s real headlines

science

GLP-1 drug ophthalmic safety reviews and prescribing regulations

Health authorities and medical societies examine rare clinical reports of optic nerve ischemia among patients taking GLP-1 receptor agonists. Pharmacovigilance reviews investigate whether rapid blood glucose reductions or direct receptor mechanics cause ocular vascular stress. The findings lead regulators to revise dosage titration guidelines and mandate boxed packaging warnings.

8 events · Runs from today to 8 January 2029

  1. Today

    The US Food and Drug Administration issues a formal safety alert warning of a potential link between GLP-1 receptor agonists and rare optic nerve ischemia.

    Where the story stands today. The forecast starts from here.

  2. 11 January 2027week 8

    Eye doctors recommend retinal scans for patients on weight-loss drugs

    Guidance follows medical inquiries into rare vision loss among users of high-dose treatments.

    base case74%

    — The American Academy of Ophthalmology urged doctors on Monday to order retinal scans before starting patients on high doses of semaglutide or tirzepatide. The advice follows reviews of rare blood-flow blockages in the optic nerve. Private eye clinics saw an immediate rise in scan bookings, while insurers began assessing whether to pay for the tests.

  3. 5 April 2027week 20

    Europe begins safety review into GLP-1 drugs and vision loss

    Health bodies will pool clinical data across member states to examine reports of optic nerve damage.

    base case72%

    — European Medicines Agency safety committees began a formal review into reports of eye damage linked to GLP-1 drugs across member states. The inquiry focuses on incidents of ischemic optic neuropathy among patients using the medicines. Drugmakers have now set up medical research panels to study blood flow in the eye.

  4. 26 July 2027week 36

    Study links GLP-1 weight-loss drugs to microvascular eye damage

    The review of 60,000 patients found a small but clear rise in risk to the optic nerve.

    base case70%

    — A study of sixty thousand patients published in the New England Journal of Medicine found a small but statistically significant link between GLP-1 drugs and optic nerve disease. The researchers noted signs of microvascular damage among some users. Medical bodies are now advising doctors to increase doses more slowly to avoid sudden changes in blood pressure.

  5. 29 November 2027week 54

    Court halts television adverts for high-dose weight-loss injections

    An injunction blocks commercial broadcasts as optic nerve safety reviews proceed.

    low probability18%

    — A federal judge in Philadelphia stopped television ads for two high-dose weight-loss drugs. Drugmakers must pull broadcast spots immediately, redirecting ad budgets into physician education. The advertising curbs now face review before the federal appeals court.

  6. 3 April 2028week 72

    FDA requires boxed vision warning on popular weight-loss drugs

    New packaging flags rare nerve injury and advises regular sight screenings.

    base case68%

    — US regulators ordered drugmakers to print boxed warnings on all GLP-1 weight-loss injections following reports of optic nerve damage. The notice tells doctors to monitor patients for sudden vision loss. Pharmacies must now hand out revised safety leaflets every time they fill a prescription.

  7. 21 August 2028week 92

    Drugmakers slow weight-loss dose steps over eye risks

    A twelve-week titration protocol aims to protect optic blood flow in patients taking GLP-1 drugs.

    base case72%

    — Drug manufacturers revised dosing schedules for GLP-1 treatments on Thursday to slow how quickly patients step up to higher amounts. The change aims to prevent rapid shifts in blood pressure around the eyes that had caused vision problems in rare cases. Prescribers have started moving patients to a twelve-week escalation plan.

  8. 8 January 2029week 112

    WHO certifies revised rules for GLP-1 prescribing

    The review establishes standardized checks after rare reports of optic nerve damage.

    base case75%

    — The World Health Organization finished its safety review of GLP-1 drugs on Monday, issuing revised prescribing instructions and monitoring standards. Health officials began the review after rare cases of optic nerve damage appeared in patients taking the metabolic medication. National health ministries will now match their packaging warnings to the global guidance.